Olmesartan Medoxomil – 50 mg

Brand:
Cayman
CAS:
144689-63-4
Storage:
-20
UN-No:
Non-Hazardous - /

Olmesartan medoxomil is an orally bioavailable prodrug form of olmesartan (Item No. 23412), a nonpeptide angiotensin II antagonist that is selective for the angiotensin 1 (AT1) receptor over the AT2 receptor.{20965} Olmesartan medoxomil (0.1 mg/kg) inhibits the angiotensin II pressor response in normotensive rats. It reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, when administered at a dose of 10 mg/kg per day, as well as in chow-fed control animals when administered at a dose of 11.4 mg/kg per day.{42446} Olmesartan medoxomil also inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats. Formulations containing olmesartan medoxomil have been used in the treatment of hypertension.  

 

Available on backorder

SKU: 11614 - 50 mg Category:

Description

A prodrug form of olmesartan; inhibits the angiotensin II pressor response in normotensive rats at 0.1 mg/kg; reduces both systolic and diastolic blood pressure in fructose-fed rats, a model of insulin resistance, at 10 mg/kg per day, as well as in chow-fed control animals at 11.4 mg/kg per day; inhibits increases in plasma levels of triglycerides and non-esterified fatty acids in fructose-fed rats


Formal name: 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2’-(2H-tetrazol-5-yl)[1,1’-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester

Synonyms:  CS 866

Molecular weight: 558.6

CAS: 144689-63-4

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Cardiovascular System|Vasculature|Vasodilation||Research Area|Endocrinology & Metabolism|Hormones & Receptors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias